Analyst Ratings for Supernus Pharmaceuticals (SUPN)
SUPN Rating Summary
SUPN Price Target Summary
- Highest: $65.00 (Piper Sandler)
- Lowest: $55.00 (Stifel)
- Average: $62.50
* Over Last 12-Mos
Overall Rating:
BUY
Rating Trend:
Avg. $ Target:
$62.50 (+41.9%)
* Over Last 12-Mos
Rating Score: 7.5 / 10
Percentile Rank: 79%
Avg. $ Target:
$62.50 (+41.9%)
* Over Last 12-Mos
Rating Score: 7.5 / 10
Percentile Rank: 79%
| Date | Firm | Analyst | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 10/29/2025 | BofA Securities » Updated 4/27/2026 |
Pavan Patel | New Coverage | Buy (N/A) |
62.00 (65.00) |
53.17 (44.04) |
-17.17% | Details |
| 10/9/2025 | Piper Sandler » Updated 10/17/2025 |
David Amsellem | Upgrade | Overweight (Neutral) |
65.00 (N/A) |
48.07 (44.04) |
-8.38% | Details |
 |
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
